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Background: Hepatitis C virus (HCV) shows a remarkable genetic diversity, contributing to its high persistence and
varied susceptibilities to antiviral treatment. Previous studies have reported that the substitution of amino acids in
the HCV subgenotype 1b core protein in infected patients is associated with a poor response to pegylated
interferon and ribavirin (PEG-IFN/RBV) combined therapy.
Objectives: Because the role of the core protein in HCV genotype 4 infections is unclear, we aimed in this study to
compare the full-length core protein sequences of HCV genotype 4 between Saudi patients who responded (SVR)
and did not respond (non-SVR) to PEG-IFN/RBV therapy.
Study design: Direct sequencing of the full-length core protein and bioinformatics sequence analysis were utilized.
Results: Our data revealed that there is a significant association between core protein mutations, particularly at
position 70 (Arg70Gln), and treatment outcome in HCV subgenotype 4d patients. However, HCV subgenotype 4a
showed no significant association between core protein mutations and treatment outcome. In addition, amino acid
residue at position 91 was well-conserved among studied patients where Cys91 is the dominant amino acid residue.
Conclusions: These findings provide a new insight into HCV genotype 4 among affected Saudi population where
the knowledge of HCV core gene polymorphisms is inadequate.
Keywords: Hepatitis C Virus (HCV) Treatment, Genotype 4, PEG-IFN/RBV combined therapyBackground
Hepatitis C virus (HCV) infects more than 170 million
people worldwide leading to chronic hepatitis, cirrhosis
and hepatocellular carcinoma [1]. HCV belongs to the
family Flaviviridae and is a member of hepacivirus genus.
It is classified into seven genotypes and numerous subtypes
[2,3]. HCV has a single-stranded RNA that encodes a poly-
protein which subsequently gets cleaved into number of* Correspondence: aqahtani@kfshrc.edu.sa
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unless otherwise stated.structural and non-structural proteins. Although the func-
tion of each protein has been intensively studied, the point
mutations that occur in various positions and cause anti-
viral drug resistance are largely unknown. Therefore, the
study of variation at the nucleotide sequence of HCV, core
protein in particular, from different geographical region is
important to understand its prevalence in the world as well
as its clinical management.
Recently, advances in HCV treatment have led to the
development of many direct-acting antiviral (DAA) agents.
Early this year, the U.S. Food and Drug Administration
(FDA) has approved a new therapy (simeprevir) to treat
chronic HCV infection [4]. However, the standard treat-
ment for chronic hepatitis C infection in the developing
countries is pegylated interferon (PEG-IFN) plus ribavirinral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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attain a sustained virological response (SVR) [5]. There
are serious side-effects and high medical cost that are
associated with PEG-IFN/RBV treatment. As a result, it
is important to predict the response to therapy for each
individual patient beforehand. Previous studies have shown
that the sequence polymorphisms within viral proteins,
such as core protein, correlate with IFN-based treatment
outcome. For example, substitutions of amino acid 70 and/
or 91 in HCV subgenotype 1b core protein are predictors
of poor response to PEG-IFN/RBV treatment [6,7]. The
clinical advantage of predicting SVR to PEG-IFN/RBV in
patients is that patients with Arg70/Lue91 residues ought
to continue the treatment course with predicted positive
response. However, in patients who have mutated resi-
dues in the core region (Gln70/Met91) would be advised
to withdraw from the treatment to avoid unnecessary
side-effects. Indeed, if a correlation between HCV core
gene mutation(s) and treatment outcome is established,
then HCV sequencing can become a noninvasive and
economical tool to assess an individual status and re-
sponse to a treatment.
Although HCV genotype 4 is the cause of approximately
20% of HCV infection worldwide, it is poorly studied [8].
Furthermore, there are limited studies and low inform-
ative data from patients in Saudi Arabia who are infected
with HCV genotype 4. The aim of this study is to analyze
the core protein of HCV genotype 4 from Saudi patient
isolates and investigate the association between core pro-
tein sequence variations and treatment outcome.
Methods
Study patients and treatment regimens
The study protocol was approved by the local ethics
committee at King Faisal Specialist and Research Center
and written informed consent was obtained from each
patient. A total of 115 baseline (i.e., treatment-naïve) pa-
tients from three different hospitals (King Khalid University
Hospital, King Faisal Specialist Hospital and Research
Center, and Riyadh Military Hospital) in Riyadh, Saudi
Arabia, were used in this study. Exclusion criteria included
co-infection with hepatitis B or human immunodeficiency
virus, co-existent autoimmune or metabolic liver disease,
active drug-induced hepatitis, decompensated cirrhosis,
evidence of severe retinopathy, neoplastic disease, coronary
artery or cerebrovascular disease, history of clinically rele-
vant psychiatric disease. The complete treatment protocol
used for these patients was previously published [9]. HCV
RNA extraction, genotyping and subgenotyping were de-
termined using previously described methods [10]. Herein,
we presented the most dominant subgenotypes of HCV
genotype 4 that are HCV-4d and HCV-4a in each group
(SVR and non-SVR). Due to limited sample size, we ex-
cluded 4r, 4n and 4o from data analysis.HCV sequence alignment and primer design
Complete genome sequences of HCV from different
geographical regions were retrieved from the GenBank
database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Multiple
sequence alignment of the retrieved sequences was per-
formed using ClustalW module of MegAlign software
(DNASTAR, Inc.,) and the consensus sequence was
used to design degenerate primers for the core region.
Primer sequences and positions are as follows: Forward:
5' TGCTAGCCGAGTAGTGTTGG 3' (positions 246–268)
Reverse: 5' CCARTTCATCATCATRTCCCA 3' (position
1298–1318) and the amplicon size is 1045 bp.
Polymerase chain reaction (PCR)
All PCR mixtures had a total volume of 25 μl that con-
tained 1 μl of HCV cDNA, 12.5 μl of GoTaq® Green
Master Mix (Promega, Madison, USA), 1 μM of forward
and reverse primers, and sterile nuclease-free water. In
addition, appropriate positive and negative controls were
employed. PCR conditions were as follows: 2 min an ini-
tial denaturing step at 95°C, followed by 35 cycles of
30 sec denaturing step at 95°C, 1 min of annealing step
at 56°C, and 1 min of extending step at 72°C. A final ex-
tension at 72°C for 5 min was performed. PCR ampli-
cons were visualized on a 1.5% agarose gel and stained
with ethidium bromide. The positive amplicons were
processed further for PCR sequencing using ABI3730XL
sequencer (Applied Biosystems, Foster City, CA). To con-
firm positive results, nucleotide sequences were blasted
against NCBI database.
Data analysis and statistics
Sequence chromatograms of 115 full-length core gene
sequences were aligned and edited using the Lasergene
suite for sequence analysis (DNASTAR, Inc.,) [11]. Nu-
cleotide (573 bp) and amino acid (191 aa) sequences
from different patient isolates were aligned using ClustalX
module (MegAlign, DNASTAR, Inc.). Full-length core
gene sequences of HCV genotype 4 were retrieved from
GenBank and used in this study as references. BioEdit
program was used to visually display the full-length core
protein with genotype corresponding references [12]. In
addition, phylogenetic tree was constructed using HCV
genotype 4 patient sequences (all subgenotypes were in-
cluded) and 20 random sequence references. The neighbor-
joining method with a bootstrap value of 1,000 replications
was employed in constructing the tree using Mega 5.0 soft-
ware [13].
Further, detecting the most statistically significant dif-
ferences between the responders and non-responders
groups was done using the Viral Epidemiology Signature
Pattern Analysis (VESPA) tool, provided by HCV sequence
database [14]. Numerical data were analyzed by Student’s t
test using STATA IC/13 software (StataCorpLP, Houston,
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significant.Results
Response to PEG-IFN/RBV therapy
One hundred and fifteen (115) patients with chronic HCV
genotype 4 were enrolled in this study. The patients’ clin-
ical characteristics are presented in Table 1. Notably, there
was no significant association between the response to
treatment and age, gender, weight, liver enzymes, HCV
viral load, disease stage, and grade. However, there is a sig-
nificant association between subgenotypes and treatment
response. Indeed, SVR rate in HCV-4a is 58% while the
SVR rate in HCV-4d is lower (35%) (P value = 0.02).
Twenty four weeks after the completion of 48 weeks of
PEG-IFN/RBV combined treatment; patients were tested
and then divided to responders (i.e., SVR (48%)) and non-
responders (i.e., non-SVR (51%)). HCV genotype 4 meanTable 1 Patient characteristics of all patients enrolled in
this study
Variable R NR P-value
Age (yrs.)
Mean ± SD* 45.82 ± 14.67 49.19 ± 15.26 0.152c
Median (25th-75th)¶ 48.00(35.50-57.00) 52.50(44.50-59.00) 0.095a
Sex§
Male count (%) 21(37.5%) 22(37.3%) 0.862b
Female count (%) 35(62.5%) 37(62.7%)
Weight (kg)* 74.54 ± 28.01 76.04 ± 18.81 0.609c
Bil (mg/dL)* 10.54 ± 4.89 12.09 ±6.83 0.42c
ALT (IU/L)* 76.59 ±57.5 82.2 ± 76.2 0.424c
AST (IU/L)* 59.27 ± 43.37 53.63 ± 55.81 0.14c
ALP (IU/L)* 98.4 ± 67.8 116.13 ± 60.98 0.538c
AFP (ng/mL)* 8.22 ±17.12 7.76 ± 18.18.47 0.904c
HCV load log10¶ 5.74(5.21-6.40) 5.88(5.15-6.48) 0.837a
Median (25th-75th)¶
Stage§
≤2 count (%) 24(77.4%) 21(63.6%) 0.227b
≥3 count (%) 7(22.6%) 12(36.4%)
Grade§
≥1 count (%) 8(25%) 8(22.2%) 0.788b
3 count (%) 24(75%) 28(77.8%)
Genotypes§
4a (%) 39(58%) 28(42%) 0.02b
4d (%) 17(35%) 31(65%)
Bil, Bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
ALP, alkaline phosphatase, AFP, α-fetoprotein.
*Values are expressed as Mean±SD, ¶values are expressed as median
(interquartile range), §count (%).
a:Nonparametric test (Mann–Whitney U test), b:Chi-squared test,
c:independent t-test.genetic distance was calculated between SVR and non-
SVR patients (Table 2). All reported sequences in this
study were deposited in the GenBank and were assigned
the following accession numbers (KC143812 - KC143908).
Phylogenetic analysis of SVR and non-SVR patients
Phylogenetic analysis of core sequences provides informa-
tion about overall relatedness of core gene among HCV
genotype 4 isolates. One hundred fifteen sequences of
HCV-4 core gene from SVR and non-SVR groups were
used to construct the tree (Figure 1). HCV-4 sequences
showed no clustering based on response to the treatment
but rather they clustered to the respective subgenotypes
correctly (i.e. HCV-4a and -4d).
Multiple sequence alignment of the core protein
Figures 2 and 3 showed aligned amino acid residues from
each group/subgenotype. Figure 2A represents HCV-4a in
SVR patients and revealed that the residue at position 70
(Arg70) and 91 (Cys91) are well conserved among these
isolates. On the other hand, our data revealed different
point mutations in the core region of HCV-4a in SVR
group. At position 60, for example, G (Gly60) mutated to
E (Glu60) in 12% of the clinical samples (Figure 2A). Pos-
ition 71 also has S (Ser71) in 80% of the samples. Position
158 showed substitution of L (Lue158) to V (Val158) in 82%
of the samples. In HCV subgenotype 4a non-SVR patients,
however, the amino acid alignment figure revealed that
position 70 (Arg70) is mutated to (Gln70) in only 18.5%
of the clinical samples. However, position 71 showed a
higher mutation rate were 70% of the clinical samples
have S (Ser71) instead of P (Pro71). Position 60 showed
another point mutation that was calculated to be 26% of
the clinical samples where E (Glu60) substitutes G (Gly60).
There was no significant correlation between core protein
sequences and treatment outcome. Notably, our patient
sequences showed a 100% mismatch with the reference
sequence in positions such as 114 (G114R) and 146 (S146G)
in HCV-4a (Figure 2).
Figure 3A showed HCV subgenotype 4d in SVR pa-
tients where the amino acid alignment revealed that the
residue at position 70 (Arg70) is mutated to (Gln70) in
29% of the clinical samples. Position 71 has a point mu-
tation where P (Pro71) is substituted with S (Ser71) in
only 2% while position 157 has a mutation of L (Leu157)
to A (Ala157) in 23% of the clinical samples. Moreover,
position 162 has mutation of V (Val162) to I (Iso162) in
23%. In non-SVR patients, however, 58% of the clinical
samples have mutation at position 70 whereas (Arg70) is
mutated to (Gln70). Moreover, at position 157, 29% of
the clinical samples showed mutation of L (Leu157) to V
(Val157), however, this amino acid substitution is different
than the mutated amino acid in SVR group (A vs. V).
There was a significant correlation between HCV-4d core
Table 2 Summary of sequence analyses of HCV-4 and mean genetic distance




4a SVR* 39 1 0.0221 0.027
Non-SVR 28 1 0.0225
4d SVR 17 1 0.0173 0.016
Non-SVR 31 1 0.0133
*Sustained Virological Response.

































Figure 1 Phylogenetic tree constructed from sequences of the
HCV-4 core protein using neighbor-joining algorithm method.
Bootstrap values corresponding to 1000 replications are indicated
below the branches and only bootstrap values > 50% were
included. Elongated triangles represent the compressed subtrees
with captions indicating HCV isolates and references. The thickness
of the triangles is proportional to the number of taxa included and
the length of the triangle corresponds to the respective diversity.
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(P value = 0.02). Moreover, our patient sequences showed
a 100% mismatch with the reference sequence in positions
such as 12 (Q12K), 20 (T20M) and 74 (K74R) in HCV-4d
(Figure 3).
Patterns discovery and recognition
Positional variations of the core protein were com-
pared using Viral Epidemiology Signature Pattern Analysis
(VESPA). Results revealed that the variations in HCV 4a
SVR and non-SVR patients are not statistically significant
(Figure 4A), while, the signature pattern analysis of HCV
4d SVR and non-SVR was statistically significant at pos-
ition 70 (Arg70Gln) (P value < 0.05) (Figure 4B).
Discussion
The HCV core gene is the genetic region that encodes
for the viral nucleocapsid protein. It consists of 191
amino acid residues that are divided into three domains,
an N-terminal hydrophilic domain (D1, residues 1–117), a
C-terminal hydrophobic domain (D2, residues 118–170),
and the last 21 amino acids that serve as signal peptide for
the downstream envelope protein E1 [15,16]. It has been
shown that the core protein is associated with number of
cellular proteins and pathways that have direct effect on
HCV lifecycle and biology [17]. Also, HCV core protein
has been suggested to have a role on antiviral activity of
IFN inhibition through interaction with the cellular pro-
tein, STAT1 [18]. Therefore, mutations in this protein
have the potential to alter the viral structure leading to
unexpected functions such as poor response to PEG-IFN/
RBV therapy. Previous studies have shown that there is a
significant correlation between mutations in the core pro-
tein and poor treatment outcome. In particular, patients
who had substitutions of Arg70 to Gln70 and/or Leu91 to
Met91 showed lower response to PEG-IFN/RBV combined
therapy [19,20]. However, most of these studies have been
conducted on Asian populations, especially Japanese
patients, who were diagnosed with HCV genotype 1b.
Herein, we hypothesized that the amino acid substitu-
tions in HCV genotype 4 (subgenotypes 4a and 4d) core
region could correlate with treatment outcome. HCV sub-
genotype 4d showed that there is a significant association
between core protein mutations, particularly at position
A) B)
Figure 2 Amino acid alignment of the core protein of HCV-4a patient isolates. A) Represents SVR patient amino acid sequences.
B) Represents non-SVR patient amino acid sequences. Amino acid positions are indicated in the upper part of the figure (i.e. reference sequence).
Dots indicate amino acid residues that are similar to the reference sequence while the single-letter code shows amino acid substitutions.
Alhamlan et al. Journal of Translational Medicine 2014, 12:91 Page 5 of 8
http://www.translational-medicine.com/content/12/1/91
A) B)
Figure 3 Amino acid alignment of the core protein of HCV-4d patient isolates. A) Represents SVR patient amino acid sequences.
B) Represents non-SVR patient amino acid sequences. Amino acid positions are indicated in the upper part of the figure (i.e. reference sequence).
Dots indicate amino acid residues that are similar to the reference sequence while the single-letter code shows amino acid substitutions.
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acid substitutions in HCV-4a showed no associations with
treatment outcome. The residue at position 70 of the core
protein was Arg70 in most of HCV-4a SVR patient isolates
and only 17% of HCV-4a non-SVR patient isolates weremutated to Gln70. Moreover, the residue at position 91 of
the core protein was well-conserved among HCV geno-
type 4.
There are several factors (predictors) that could con-
trol the effectiveness of the treatment and such factors
Figure 4 Viral Epidemiology Signature Pattern Analysis (VESPA). The query sequence is the SVR group while the background sequence is
the non-SVR group. The dots (.) in the signatures indicate that the two sequences agree in those positions while the letter indicates a statistically
significant position. A) In HCV subgenotype 4a, no signature pattern between the two groups of responders and non-responders was found.
B) HCV subgenotype 4d results revealed one signature pattern between the query signature (SVR) and Background signature (non-SVR) in
genotype 4d. This signature is at position 70, where it is associated with amino acid Arginine (R) in SVR group compared to amino acid Glutamine
(Q) in non-SVR group. Statistically significant variations were calculated with a threshold of P < 0.05.
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tors include age, gender, patient body weight, ethnicity,
alcohol consumption and host genetic variations. Several
recent studies have shown that single nucleotide poly-
morphisms (SNPs) in IL-28B gene region are associated
with response to combination therapy with pegylated
IFN-α and ribavirin [21]. On the other hand, virus geno-
types and viral load have been shown to modulate treat-
ment outcome [6,22]. Based on previous studies, HCV
genotype is the most significant factor affecting treat-
ment responses [23]. While HCV genotype 2 and 3 have
the highest rate of SVR to PEG-IFN/RBV treatment (80%),
HCV genotype 1 and 4 are showing more resistance to
treatment (50-60%) [24,25]. Notably, the present study re-
vealed that the SVR rate in HCV-4a is higher (58%) than
HCV-4d (35%) indicating a role of the subgenotyping
in treatment response. The differences in responding to
the treatment among different genotypes and subgeno-
types suggest a role of the viral sequence variations. It is
noteworthy that most previous studies were conducted
on Asian population. Thus, further investigations are
needed to explore this phenomenon in different ethnic
populations.
In recent studies, El-Shamy et al. has investigated 43
Egyptian patients who were infected with HCV genotype 4
(mostly subgenotype 4a) and revealed that no significant
correlation between core protein amino acid substitutions
at position 70 and/or 91 and treatment outcome [26]. Our
finding in regard to HCV-4a is in agreement with the
aforementioned report that the substitutions at positions
70 and/or 91 are not associated with antiviral resistance.However, in HCV-4d patient isolates, our data revealed
that there is a significant association between core amino
acid substitutions, particularly at position 70 and treatment
outcome. Phylogenetic analysis and sequence comparison
showed that no clustering was observed based on treat-
ment response but rather they grouped to the correspond-
ing subgenotypes correctly (i.e. HCV-4a, −4d).
Conclusions
The present study revealed that HCV-4d has a point muta-
tion at position 70 (Arg70Gln) that is statistically significant.
However, no evidence was found in HCV-4a for the effect
of core protein polymorphisms, either at position 70 and/or
91, and treatment outcome. Instead, mutations were scat-
tered over the full-length core region with no specific asso-
ciation with drug resistance. Although several possibilities
have been proposed to explain the effect of amino acid sub-
stitutions of core protein on treatment outcome, the exact
mechanism has not been determined. Nonetheless, this
study emphasizes the fact that single nucleotide muta-
tions in the core gene could prove helpful in predicting
the treatment outcome, at least in sub-genotype 4d-
infcted patients.
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